The latest selling price of brigatinib/brigatinib after being included in medical insurance

Brigatinib is a treatment for adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). The drug's use is based on U.S. Food and Drug Administration (FDA) approval and is limited to ALK-positive patients. Before deciding to use brigatinib, doctors will determine the ALK-positive status based on the patient's tumor sample test results.

Brigatinib, as an ALK inhibitor, was first discovered in the study of anaplastic large cell lymphoma (ALCL). ALK chromosomal rearrangements were discovered. Given that ALK is barely expressed in normal adult tissues, this makes it a promising molecular target in cancer therapy. Brigatinib not only inhibits the fusion of reactive oxygen species proto-oncogene-1, but also inhibits EGFR mutations and has a significant therapeutic effect on the central nervous system.

Currently, the original drug of brigatinib has been launched in China and has been included in the Class B medical insurance drug catalog. The specifications of the drugs that can be seen on the market include: 30mg in 14-piece 2-pack, 90mg in 7-piece or 7-piece 4-pack, and 180mg in 7-piece 4-pack. Although the drug has been included in medical insurance, its original price is still high, with each box selling for about 10,000 yuan. However, due to different medical insurance reimbursement ratios in various regions, the actual price paid will vary. Please consult your local medical insurance bureau or hospital for specific prices.

In addition, overseas markets also provide generic brigatinib drugs at more affordable prices. The main ingredients of these generic drugs are almost the same as the original drugs sold at home and abroad. For example, a 90mg 30-tablet generic drug produced by a Bangladeshi pharmaceutical factory costs only about 2,000 yuan per box (the price may change due to exchange rate fluctuations).